Cargando…
COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature
The global pandemic of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented newfound challenges to the oncology community regarding management of disease progression in immunocompromised and cancer patients. Further, the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482717/ https://www.ncbi.nlm.nih.gov/pubmed/34579537 http://dx.doi.org/10.1177/10732748211044361 |
_version_ | 1784576968019148800 |
---|---|
author | Patel, Raj H. Vanaparthy, Rachana Greene, John N. |
author_facet | Patel, Raj H. Vanaparthy, Rachana Greene, John N. |
author_sort | Patel, Raj H. |
collection | PubMed |
description | The global pandemic of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented newfound challenges to the oncology community regarding management of disease progression in immunocompromised and cancer patients. Further, the large influx of COVID-19 patients has overwhelmed healthcare facilities, limited access to intensive care unit beds and ventilators, and canceled elective surgeries causing disruptions to the cancer care continuum and re-organization of oncological care. While it is known that the potential threat of infection is greatest in elderly patients (>60 years of age) and patients with underlying comorbidities, there is still insufficient data to determine the risk of COVID-19 in cancer patients. Given the immunosuppressive status in cancer patients arising from chemotherapy and other comorbidities, management of COVID-19 in this patient population carries a unique set of challenges. We report three cases of COVID-19 in immunocompromised cancer patients and discuss the challenges in preventing, diagnosing, and treating this vulnerable group. |
format | Online Article Text |
id | pubmed-8482717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84827172021-10-01 COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature Patel, Raj H. Vanaparthy, Rachana Greene, John N. Cancer Control Review The global pandemic of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented newfound challenges to the oncology community regarding management of disease progression in immunocompromised and cancer patients. Further, the large influx of COVID-19 patients has overwhelmed healthcare facilities, limited access to intensive care unit beds and ventilators, and canceled elective surgeries causing disruptions to the cancer care continuum and re-organization of oncological care. While it is known that the potential threat of infection is greatest in elderly patients (>60 years of age) and patients with underlying comorbidities, there is still insufficient data to determine the risk of COVID-19 in cancer patients. Given the immunosuppressive status in cancer patients arising from chemotherapy and other comorbidities, management of COVID-19 in this patient population carries a unique set of challenges. We report three cases of COVID-19 in immunocompromised cancer patients and discuss the challenges in preventing, diagnosing, and treating this vulnerable group. SAGE Publications 2021-09-28 /pmc/articles/PMC8482717/ /pubmed/34579537 http://dx.doi.org/10.1177/10732748211044361 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Patel, Raj H. Vanaparthy, Rachana Greene, John N. COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature |
title | COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature |
title_full | COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature |
title_fullStr | COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature |
title_full_unstemmed | COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature |
title_short | COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature |
title_sort | covid-19 in immunocompromised cancer patients: a case series and review of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482717/ https://www.ncbi.nlm.nih.gov/pubmed/34579537 http://dx.doi.org/10.1177/10732748211044361 |
work_keys_str_mv | AT patelrajh covid19inimmunocompromisedcancerpatientsacaseseriesandreviewoftheliterature AT vanaparthyrachana covid19inimmunocompromisedcancerpatientsacaseseriesandreviewoftheliterature AT greenejohnn covid19inimmunocompromisedcancerpatientsacaseseriesandreviewoftheliterature |